Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes
J Clin Oncol. 2009 Jun 15, D Steensma , M Baer, J Slack, R Buckstein, L Godley, G Garcia-Manero, M Albitar, J Larsen, S Arora, M Cullen, H Kantarjian
TAKE-HOME MESSAGE
Abstract
Abstract
Purpose: Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m2 administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices. Patients and Methods: Patients were treated with decitabine 20 mg/m2...
SUMMARY
OncologySTAT Editorial Team
Myelodysplastic syndrome (MDS) is a group of diverse clonal disorders characterized by abnormalities in hematopoietic cells and bone marrow failure. The Food and Drug Administration approved decitabine for MDS after favorable results from a phase III study in which it was administered at a dose of 15 mg/m2 intravenously over 3 hours every 8 hours for 3 consecutive days. The response rate for decitabine was 30%, compared with 7% for supportive care alone. Previously, Kantarjian et al studied several...
